問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Cardiovascular Diseases

Division of Cardiovascular Diseases

MacKay Memorial Hospital (在職)

Division of Cardiovascular Diseases

Division of Cardiovascular Diseases

馬偕紀念醫院佳生臨床藥理試驗中心_佳永生技股份有限公司

Division of Cardiovascular Diseases

更新時間：2023-09-19

廖峰慶
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

13Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖峰慶

List

14Cases

2024-09-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2026-03-01 - 2030-10-09

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2023-02-01 - 2025-12-31

Phase III

Completed
An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG)

  • Condition/Disease

    Severe Hypertriglyceridemia

  • Test Drug

    Olezarsen (ISIS 678354)

Participate Sites
7Sites

Recruiting7Sites

2024-08-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-05-01 - 2029-12-31

Phase III

Active
A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia

  • Condition/Disease

    Hypercholesterolemia

  • Test Drug

    tablet

Participate Sites
10Sites

Recruiting10Sites

2023-03-01 - 2027-04-30

Phase III

Active
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

  • Condition/Disease

    Atherosclerotic Cardiovascular Disease

  • Test Drug

    olpasiran (AMG 890)

Participate Sites
10Sites

Recruiting9Sites

Terminated1Sites

王怡智
National Taiwan University Hospital

Division of General Internal Medicine

2019-05-02 - 2026-01-17

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2025-08-29 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-10-01 - 2027-12-31

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity

  • Condition/Disease

    Overweight

  • Test Drug

    Tirzepatide（LY3298176）

Participate Sites
11Sites

Not yet recruiting2Sites

Recruiting9Sites

2019-05-02 - 2026-01-17

Phase III

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  • Condition/Disease

    Coronary Heart Disease (CHD)

  • Test Drug

    Repatha

Participate Sites
10Sites

Recruiting9Sites

Terminated1Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB